Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Amazon Explores AI Content Marketplace With Media Publishers 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Heidelberg, Germany, November 15, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15, 2017, at 4:00 pm GMT.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], [email protected]
